Potential mechanisms of resistance to venetoclax and strategies to circumvent it

BACKGROUND: Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior therapy. It is also being evaluated in numerous clinical trials for treating pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahir, Stephen K., Smith, Morey L., Hessler, Paul, Rapp, Lisa Roberts, Idler, Kenneth B., Park, Chang H., Leverson, Joel D., Lam, Lloyd T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457565/
https://www.ncbi.nlm.nih.gov/pubmed/28578655
http://dx.doi.org/10.1186/s12885-017-3383-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457565/
https://www.ncbi.nlm.nih.gov/pubmed/28578655
http://dx.doi.org/10.1186/s12885-017-3383-5

Ejemplares similares